[Assessment of proliferation: core biopsy or resection specimen? Discrepancies in breast cancer with low and high proliferation].

Der Pathologe
E C ObermannCoya Tapia

Abstract

The assessment of the proliferation fraction is becoming more and more important; however, there is no consensus concerning optimal validation. Depending on the institute the proliferation fraction is determined either from a core biopsy (SB) or resection specimen (OP). The interobserver variability and the results of SB and OP were investigated whereby two pathologists independently estimated the proliferation fraction of 90 cases of invasive breast cancer. The results (Ki-67) were quantified, categorized, and compared. Identical (accuracy of 5% steps) results between the 2 pathologists were achieved in 43% (n=39) for SB, 47% (n=42) for OP and 60% (n=54) for SB versus OP. When categorizing the proliferation fraction (low  ≤ 15%, moderate 20-30% and high  ≥ 35%) the following results were achieved: 76% (n=68) for SB, 82% (n=74) for OP and 81% (n=73) for SB versus OP. There was a clear interobserver variability (SB: kappa=0.32, OP: kappa=0.34) but this could be dramatically improved by forming proliferation categories (SB: kappa=0.62, OP: kappa=0.72, 60 versus 81%). In SB with a low proliferation fraction a repeated analysis in OPs can be advisable as a higher proliferation fraction is observed in up to 12% of OPs.

References

Jan 15, 1983·International Journal of Cancer. Journal International Du Cancer·J GerdesH Stein
Nov 13, 2004·Applied Immunohistochemistry & Molecular Morphology : AIMM·Suash SharmaRaheela Ashfaq
Jan 11, 2005·Cancer Letters·Antonio CavaliereEmilio Bucciarelli
Feb 8, 2005·The Breast : Official Journal of the European Society of Mastology·C BadoualP Michenet
Jan 1, 2008·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·A NeriF Roviello
Nov 5, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe VialeUNKNOWN Breast International Group Trial 1-98
Jun 19, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Sep 5, 2009·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Reiki NishimuraNobuyuki Arima
Feb 16, 2010·The Lancet Oncology·Rinat YerushalmiKaren A Gelmon
Jul 14, 2010·Breast Cancer Research and Treatment·Mohammed A AleskandaranyAndrew R Green
Sep 16, 2010·Journal of Cancer·Yi-Hsuan HsiaoYan-Gao Man
Feb 10, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MalvezziE Negri
Oct 1, 2011·Journal of the National Cancer Institute·Mitch DowsettUNKNOWN International Ki-67 in Breast Cancer Working Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.

Related Papers

The Journal of Endocrinology
Rob H P HilgersHerjan J T Coelingh Bennink
The Journal of Clinical Endocrinology and Metabolism
J Fishman
Journal of the National Cancer Institute
Mei-Yin C PolleyInternational Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group
Contraception
Herjan J T Coelingh BenninkChristian F Holinka
© 2021 Meta ULC. All rights reserved